Article Details
Retrieved on: 2018-02-21 19:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>NEW YORK, Feb. 22, 2018 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $66 million Series B financing and significant progress in building an industry-leading research program.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here